EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial

Amir Razaghizad iD, Jiayi Ni, Pedro Marques iD, Thomas A Mavrakanas, Michael A Tsoukas iD, Elite Possik, Thao Huynh, Jodi D Edwards, Peter Liu, Walter Swardfager, Frederic Baroz iD, João Pedro Ferreira iD and 1 more

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15768 ↗

At a glance

Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2024. Written by Amir Razaghizad and 12 co-authors. Institution: Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. Major MEDLINE topics: Diabetes Mellitus, Type 2, Canagliflozin, Phenotype, Sodium-Glucose Transporter 2 Inhibitors. Cited 6 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Dr. Clarke K. McLeod Memorial Scholarship Fund, Mach-Gaensslen Foundation of Canada Scholarship, Canada Research Chairs Program.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aim

To identify unique clinical phenotypes in type 2 diabetes (T2D) and investigate their treatment response to canagliflozin using latent class analysis.

Methods

This was a pooled latent class analysis of the individuals in the CANVAS Program and CREDENCE trial. The co‐primary endpoints were hospitalization for heart failure (HHF) and the composite of cardiovascular death (CVD) or HHF. Secondary endpoints included three‐point major adverse CV events, its individual components, and all‐cause mortality. We completed Cox proportional hazards models to evaluate the effect of canagliflozin across phenotypes.

Results

Four distinct phenotypes were identified: Phenotype 1 ( n = 966, 6.6%), with the lowest prevalence of heart failure, kidney dysfunction and hypertension; Phenotype 2 ( n = 4169, 28.7%), primarily comprising females with a high prevalence of atherosclerotic vascular disease (ASCVD); Phenotype 3 ( n = 7108, 48.9%), predominately males with a high prevalence of ASCVD; and Phenotype 4 ( n = 2300, 15.8%), possessing the highest prevalences of HF and renal dysfunction. A hierarchical increase in the risk of the primary endpoint was observed across the phenotypes, with the highest CV risk observed for Phenotype 4 (hazard ratio for HHF: 7.57 [95% CI: 4.19‐13.69]). Canagliflozin significantly reduced HHF and the composite CVD or HHF across phenotypes (all P values for interaction > .05).

Conclusion

We identified four clinically distinct T2D phenotypes with differential CV risks. Canagliflozin reduced the risk of CV events, irrespective of the phenotype, emphasizing its broad therapeutic acceptability.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2CanagliflozinPhenotypeSodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesLatent Class AnalysisHumansMaleFemaleMiddle AgedAgedHeart FailureDiabetic AngiopathiesPrevalence

Author keywords

SGLT2 inhibitorscardiovascular eventsheart failuretype 2 diabetes

Substances

CanagliflozinSodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  • Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
  • Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
  • Department of Internal Medicine, Centro Hospitalar Universitário de S. João, Porto, Portugal.
  • Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

ORCID profiles: Amir Razaghizad, Pedro Marques, Michael A Tsoukas, Frederic Baroz, João Pedro Ferreira, Abhinav Sharma

Funding

  • Dr. Clarke K. McLeod Memorial Scholarship Fund
  • Mach-Gaensslen Foundation of Canada Scholarship
  • Canada Research Chairs Program
  • Ontario Ministry of Colleges and Universities
  • Canada Brain Research Fund

Cite

APA

Razaghizad, A., Ni, J., Marques, P., Mavrakanas, T. A., Tsoukas, M. A., Possik, E., Huynh, T., Edwards, J. D., Liu, P., Swardfager, W., Baroz, F., Ferreira, J. P., & Sharma, A. (2024). Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15768

Vancouver

Razaghizad A, Ni J, Marques P, Mavrakanas TA, Tsoukas MA, Possik E, et al. Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15768

BibTeX
@article{Razaghizad2024,
  author = {Razaghizad, Amir and Ni, Jiayi and Marques, Pedro and Mavrakanas, Thomas A and Tsoukas, Michael A and Possik, Elite and Huynh, Thao and Edwards, Jodi D and Liu, Peter and Swardfager, Walter and Baroz, Frederic and Ferreira, João Pedro and Sharma, Abhinav},
  title = {Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15768}
}
Start for free →